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Background/aim: The aim of this study was to summarize the experiences of a single medical center for genetic diagnosis and treatment
of prenatal patients.
Materials and methods: This study includes a retrospective data analysis of 2843 prenatally investigated cases using invasive methods
during a 6-year period (2013–2019) at a single tertiary care center.
Results: Chromosomal abnormalities were detected in 80 out of 1221 amniotic fluid samples;,178 out of 1608 chorionic villus samples,
and 1 out of 14 cordocentesis samples. The most common chromosomal abnormality was trisomy 21. At least one mutation was detected
in 63 of the 152 molecular tests performed on fetuses.
Conclusion: Clinical procedures such as ultrasounds and genetic tests are able to provide a better clinical follow-up for pregnant women
about the possible congenital anomalies or any genetic condition, with proper genetic counseling and testing methodology.
Key words: Prenatal diagnosis, cytogenetics, molecular testing, molecular cytogenetics, genetic counseling

1. Introduction
Prenatal diagnosis has become widely available in the
last decade and an increasing variety of anomalies can be
detected via both chromosomal analysis and DNA-based
molecular methods. There are two broad types of tests for
genetic disorders: screening tests, which evaluate the risk
of a fetus for certain genetic disorders and diagnostic tests,
which can detect specific genetic disorders actually present
in the fetus. Thus, the practice of prenatal screening is an
important step for the identification of changes, resulting
in the rapid expansion in genomic testing.
There is a plethora of genetic disorders that can be
diagnosed during pregnancy. These disorders are classified
as chromosomal anomalies, monogenic diseases, complex
disorders, and teratogenic disorders. Monogenic disorders
occur as a result of mutation(s) in a single gene. Although
the majority of genetic diseases are caused by single gene
mutations, the numerical and structural chromosomal
abnormalities are the most evaluated causes of fetal
anomalies and congenital genetic disorders [1]. The early

and precise diagnosis of such anomalies during pregnancy
is the main goal of prenatal diagnostics. The most common
aneuploidies observed in prenatal diagnosis during the
second trimester are the trisomies of chromosomes 13,
18, or 21, and the gonosomal abnormalities. Trisomy 13,
18, and 21 account for 89% of autosomal chromosomal
aneuploidy pregnancies, which can survive to term.
However, these patients mostly present with severe
phenotypes [2]. Aneuploidies are traditionally detected by
full karyotype analysis of cultured cells collected, which
has a very high diagnostic accuracy up to 99.8%. Karyotype
analyses are, therefore, the reference method for invasive
prenatal diagnosis of fetal chromosomal abnormalities.
Rapid detection of these aneuploidies following sampling
via amniocentesis is also achievable with fluorescence in
situ hybridization (FISH) by the utilization of centromere
or locus-specific probes. All these assays can be performed
via amniotic fluid or chorionic villus sampling (CVS) by
an experienced specialized clinician.
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2. Materials and methods
2.1. Patients
A retrospective survey covering the 6-year period from
2013 to 2019 at the Medical Genetics Department and
Adana Genetic Diseases Diagnosis and Treatment Center
(AGENTEM) of Çukurova University includes prenatal
analysis of CVS, amniocentesis, and cordocentesis in 2843
pregnancy cases.
The cytogenetic and molecular data of the 2843
pregnancies were obtained from amniocentesis (AS)
(1221), CVS (1608), and cordosentesis (CS) (14). Prenatal
cases in which abnormalities were detected were referred
to the medical genetics department. Conventional
prenatal karyotypic analyses were performed for all of the
subjects. All of the patients underwent an invasive prenatal
diagnosis both received pre- and posttest counseling
from an experienced genetic counselor and/or medical
geneticist.
The study protocol was approved by the local
ethics committee of the study center with a protocol
number of 13/68 (Çukurova University, Medical Faculty,
Noninterventional Clinical Research Ethics Committee,
2017).
2.2. Methods
The main indications for chromosome analysis were
advanced maternal age, increased risk based on maternal
serum screening tests, and abnormal ultrasound findings
of chromosomal aberrations. Moreover, an affected child
or a pedigree analysis revealing a positive familial history
are the indicators of molecular testing.
Conventional karyotype analysis was performed
on cultured biological samples following the European
Cytogeneticists Association Guidelines [3]. The
chromosomal abnormality determination was performed
in two simultaneously cultured flasks, which were made
for each patient sample, and at least 20 metaphases were
analyzed at the level of 450–550 banding. The FISH
analysis was carried out with commercially available
probes according to the manufacturers’ protocols. Specific
molecular analyses were performed on DNA isolated
from samples, based on family history and predefined
mutations.
3. Results
A total of 2843 fetal materials were examined and
chromosomal analyses were performed in all cases.
Fetal material cell culture failure occurred in only 3
cases; these cases were excluded from the statistical data.
Chromosomal abnormalities were detected in 80 of 1221
amniotic fluid samples, 178 of 1608 CVS samples, and in
1 of 14 cordocentesis. The most frequent chromosomal
abnormality was trisomy 21 (Down syndrome) from both
CVS and amniocentesis samples (Table 1).
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Table 1. The distribution of abnormal karyotype results.
The
The number
number
Sample Sample
with a
with an
type number
normal
abnormal
karyotype
karyotype

AS

1221

1141

80

Karyotype (N)
47,--,+21 (N = 32)
(40% of AS with
chromosomal
anomalies)
47,--,+18 (N = 15)
47,--,+13 (N = 4)
69,--- (N = 7)

CVS

1608

1430

178

Other N = 22
47,--,+21 (N = 68)
(38.2% of CVS
with chromosomal
anomalies)
47,--,+18 (N = 39)
45,X (N = 4)
47,--,+13 (N = 14)
69,--- (N = 3)
Other N = 34

CS

13

12

1

47,XX,+18

The FISH technique was used to evaluate the
microdeletion syndromes via syndrome-specific region
probes in 28 pregnancies while 26 of 28 were examined
for Di George syndrome, only 1 was analyzed for Prader–
Willi syndrome and another 1 for Cri-du-Chat syndrome.
A deletion was detected in the Cri-du-Chat FISH test, but
the rest were reported as normal.
FISH was also used to characterize 131 samples
for rapid aneuploidy, of which 94 were determined to
be normal. Of the 37 samples with a FISH-identified
chromosomal abnormality, 20 were from AS specimens
and 17 were from CVS specimens (Table 2).
Molecular testing was performed in 152 cases which
revealed 41.45% positivity rate (n = 63). The numbers
together with the most frequent genes and the mutations
detected are listed in Table 3 (all the mutations in related
genes are listed in the supplemental data (Table S1)).
4. Discussion
Genetic counseling is defined as a communication process
with individuals and their families about the genetic
diseases with the aim of risk reducing for the recurrence,
mostly through the provision of both prenatal and
postnatal diagnosis options and offering the most current
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therapies together with psychotherapeutic support [4].
Nondirectiveness is the main and basic principle that
requires the maintenance of a neutral stance of genetic
counselor in order to support and also to respect the
patient’s personal values and decisions [4,5].
A prenatal diagnosis can be either invasive or
noninvasive. Invasive prenatal sampling is necessary to
apply molecular methods if the results of genetic testing
has an impact on clinical decision-making and clinical
outcomes such as when the mother is a carrier for X-linked
diseases, or if both parents are carriers for an autosomal
recessive disorder, as well as when either of the parents is
afflicted with an autosomal dominant disease.
It is important to not forget that the prenatal genetic
testing is an optional strategy that depends on the patient’s
needs and decisions. The patients should be informed
about what the tests can reveal, before the sampling
procedures, as well as after the results are in. The major
supporting tool for a medical geneticist is the careful preand posttest counseling [6].
According to the literature, Down syndrome (trisomy
21) is the most common chromosomal abnormality, with
an incidence estimated one in 700–1000 live births. It is
considered to be one of the major congenital causes of
intellectual disability in the human population. In our
Table 2. Rapid aneuploidy FISH results with incidences.

Material
type

Total
analysis
with
abnormal
result

Mutation
detection
rate

AS

20

20/131

FISH result
(N)
Trisomy 21 (N = 10)
Trisomy 18 (N = 9)
Triploidy (N = 1)
Trisomy 21 (N = 10)

CVS

17

17/131

Trisomy 18 (N = 5)
Trisomy 13 (N = 1)
Turner S (N = 1)

study group, numerical chromosomal anomalies were
detected in 80 of the AS-diagnosed patients and Down
syndrome accounted for 32 (40%) of them. Chromosomal
anomalies were found in 178 of the CVS-sampled patients,
and Down syndrome was diagnosed in 68 (38.2%) of them.
In previous studies, the rate of chromosomal abnormalities
had been found lower than that in our study, but reported
series were also in accordance with our results as the most
common anomaly was the Down syndrome [7,8]. The
higher rates in our study depend on both the sensitivity of
screening tests applied to all pregnant women to predict
Down syndrome and a well-established clinical algorithm
of perinatology and genetic counseling together with
clinical follow-ups. The other main reason is the fact that
our center and the hospital give a healthcare service as a
reference center for prenatal diagnosis and a main hub for
genetic counseling, from children to adults. As prenatal
screening and diagnostic techniques have become more
enhanced and widely available, medical geneticists should
expect to provide information and support following a
new diagnosis of Down syndrome on a frequent basis. If
the fetus is diagnosed with Down syndrome during the
prenatal period, the common problems in Down syndrome
should be explained to the family clearly, but the decision
should be made by the family as to whether to terminate
the pregnancy.
It has been estimated that a minimum 0.05% of
newborns have unbalanced structural chromosomal
abnormalities, which encompasses pathological alterations
resulting from the breakage or exchange of chromosome
material [9,10]. However, there were no fetuses with
structural chromosomal anomalies detected among our
case series.
All of the chromosomal aberrations we detected
were previously known alterations; therefore, the
clinical outcomes were predictable and the content of
genetic counseling was clear. Uncommon chromosomal
abnormalities in prenatal diagnosis require correlations
between the cytogenetic aberrations and ultrasonography
findings. These rare chromosomal abnormalities are
very important for providing easy to understand genetic
counseling for the parents [6].

Table 3. The distribution of materials tested for specific genes and the list of the most frequent mutations detected.

Material type Total analysis

AS/ CVS/ CS

152

Mutation
detected

63

Gene

Total number of
tested samples

Total number of samples
with mutation

Total number of samples
with no mutation

SMA

17

13

CFTR

12

PAH

9

4 homozygous
2 heterozygous
1 homozygous
5 heterozygous
1 homozygous

9
3
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Prior to molecular prenatal testing, genetic counseling
should be offered to discuss the information ratio and
limitations of prenatal testing along with the consequences
of both test results with or without abnormalities
(mutations). Hence, a normal prenatal test result cannot
absolutely exclude the diagnosis of a genetic disease.
Molecular tests were performed as prenatal tests in a
152-person pregnant group. Sixty three of them identified
a mutation in the fetus. The most frequent tested genes
were spinal muscular atrophy (SMA), cystic fibrosis
(CFTR), and phenylketonuria (PAH). All of the families
with specific molecular testing had a predetermined
history of disease and mutations in the parents had been
identified before prenatal testing. The genetic counseling
and the family’s understanding of the disease was easier
due to familial history in this group.
The advances in prenatal diagnosis enabled us to plan
the antenatal care and newborn units, as well as the delivery.

Together, our data indicates the general acceptance,
carrier frequencies, and prenatal testing results in the
south-east Mediterranean region of the Turkish population.
Moreover, our study describes the first comprehensive
frequencies and risks from a large cohort tested from
a cytogenetic and molecular genetic perspective in the
region. This data can serve as a reference for future
screening and genetic counseling.
The acceptance of prenatal screening by the efforts
of medical geneticists also offers insights into the future
potential for whole exome or genome sequencing of all
known mutations causing serious diseases of newborns.
Thus, preventive medicine is also one of the main aims for
all health systems, which includes simultaneous screening
of both partners, in conjunction with prescreening genetic
counseling.
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Table S1. The full list of the genes and mutations detected by
prenatal tests.
Gene
SMA1

PAH

PCCA

BETA G.

CFTR

GALC

ARSB

HEXB

MUT
GCDH
GAA
ASAH1
PRF1
CTNS

Mutation
Exon 7–8 deletion (4
homozygous)
c.1243G>A p.D415N (het)
c.165delT p.F55Lfs*6 (het)
c.1066–11G>A IVS10-11G>A
(het)
c.1199+1G>C IVS11+1G>C
(het)
c.782G>A p.R261Q (het)
Exon 3 DEL (homozygous)
c.2010-2A>G IVS222A>G(het) (hom)
c.1746G>A p.S582S (2 hom)
c.20A>T p.E6V / c.-101C>T
(2 comp het)
IVS-I110 G>A / Hb S A-T
(comp het)
c.93-21G>A IVS1-110G>A
(hom)
c.2657+5G>A IVS14b+5G>A
(het)
c.3659C>T p.T1220I (het)
c.1521_1523delCTT
p.508delF (hom)
c.489_490delGC
p.W163Cfs*24 (het)
c.1807G>T p.G603* (het)
(hom)
c.962T>C p.L321P (2 hom)
c.1036delG p.E346Sfs* (het)
c.149_158del
CCAAGCCGGG (het)
c.1083-2A>G IVS8-2A>G
(hom)
c.668A>G p.K223R (hom)
c.1843C>A p.P615T (het)
c.743C>T p.P248L (het)
c.1228G>A p.V410M (het)
c.2237G>A p.W746* (hom)
c.1195-17_1199del
pD399Pfs*105 (het)
c.92G> p.C37F (het) (hom)
c.1122G>A p.W374* (het)
(hom)
c.451A>G p.R151G (2 het)

Table S1. (continued)
Gene

Mutation

Sample (number of
the mutation)

ABCD4

CVS (4)

AGPAT2

c.1093G>T p.G365C /
c.1411C>T p.R471W (het)
c.514G>A p.E172K (het)

CVS (4)
AS (2)

CVS (4)

AS (3)
CVS (1)

CVS (1)
AS (2)

CVS (3)

Sample (number of
the mutation)
AS
KS

ALMS1

c.6828C>G p.C2276* (het)

AS

ANTXR2

c.945T>G p.C315W (het)

CVS

ATM

c.6047A>G p.D2016G (het)

CVS

BBS7

c.947G>T p.G316V (hom)

CVS

CRTAP

c.535G>T p.E179* (het)

CVS

DMD

45-49 DEL (hom)

AS

EIF2B3

c.833A>G p.Y278C (het)

AS

ETHE1

c.487C>T p.R163W (het)

AS

FAH

c.554-1G>T IVS6-1G>T (het)

CVS

GALT

c.1046T>G p.L349R (het)

AS

GLB1

AS
CVS

IDS

c.8G>T p.G3V (hom)
c.232_234delGTT p.77delV
(het)
c.253G>A p.A85T (het)

IVD

c.157C>G p.R53G (het)

AS

NAGLU

c.733T>C p.F245L (het)

CVS

PHKA2

c.759A>C p.K253N (hem)
c.665_669TCACC
p.I222Mfs*8 (het)

CVS

(het) (hom)

CVS (2)

GNPTAB

TBC1D20
HBA1HBA2

CVS

CVS

Het: heterozygous, hom: homozygous.

CVS (3)

CVS (2)
CVS (1)
AS (1)
CVS (2)
CVS (2)
CVS (1) AS(1)
CVS (2)
AS (2)

1

